We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. serves customers who are accelerating life sciences research, solving complex analytica... read more Featured Products: More products

Download Mobile App





New HPLC Quadruples Clinical Throughput Capabilities, Displayed at AACC 2015

By LabMedica International staff writers
Posted on 28 Jul 2015
A new Class-I, four-channel HPLC that enables labs to increase efficiency by performing multiple parallel LC-MS separations simultaneously in a single instrument, is being exhibited at the AACC 2015 Meeting & Clinical Lab Expo (July 26-30; Atlanta, GA, USA) in Booth 3135.

Thermo Fisher Scientific Inc. More...
(Waltham, MA, USA) now offers its new Prelude LX-4 MD HPLC, listed with the FDA as a Class I medical device for general clinical use. Prelude LX-4 MD HPLC quadruples the productivity of a single-channel HPLC by using four parallel channels to deliver up to 4 separations in a single instrument, streamlining LC-MS workflows, reducing mass spectrometer idle time, and keeping free valuable bench space. The four channels can run identical or different LC-MS assays simultaneously, providing flexibility for varying clinical separations and maximizing mass spectrometer utilization.

"We are strongly committed to bringing the advantages of LC-MS to the clinical market,” said Bradley Hart, Thermo Fisher Scientific, “The Prelude LX-4 MD is one of the first products within a broader initiative to make sample separations and mass spectrometry more useful and accessible to the clinician.”

Prelude LX-4 MD is the newest addition to the family of Thermo Scientific chromatography and mass spectrometry instruments and software for the clinical lab, which includes the Endura MD triple quadrupole mass spectrometer, Prelude MD HPLC, and software ClinQuan MD.

Related Links:

Thermo Fisher Scientific
Thermo Scientific Clinical Diagnostics
American Association for Clinical Chemistry (AACC)



New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.